Called Neffy, it offers a needle-free alternative to the EpiPen used by those at risk of potentially fatal anaphylaxis to inject themselves with adrenaline.

Alnylam Pharmaceuticals Inc. ALNY) on Thursday reported third-quarter net income of $251.1 million, after reporting a loss in the same period a year earlier.

CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully ...

The early-stage pipeline for amyotrophic lateral sclerosis drugs exploded last year. After ALS R&D notched 28 new trial ...

A year after Boston's inclusionary zoning policy was made more aggressive, developers and politicians have criticized it for ...

A Canadian’s plan to bring his late celebrity wife back to life in AI form has raised a host of ethical questions about prolonging human existence in the digital universe. Alan Hamel, a Canadian ...

President Trump’s sweeping legislation is bringing dramatic changes to Medicaid, SNAP, and other government programs — and ...

Zhang Xin rose from poverty to become a self-made billionaire dubbed “the woman who built Beijing” by building a property ...

Rob Edwards’ journey has taken him from teenage prodigy at Carlisle United, to stints at Bristol City, Preston and Exeter and ...

Cannabix Technologies Inc. (the "Company or Cannabix") is pleased to report that the United States Patent and Trademark Office (USPTO) has granted patent No. 18/1729,658 entitled, "Contact-Free Breath ...

Meanwhile in the UK, softer inflation data means the Bank of England's interest rate call on Thursday next week is more finely balanced than previously thought. A hold is broadly expected, but the ...

Attima Hadlari, a longtime board member of Nunavut Tunngavik Inc. (NTI), drum dancer and founding president of Red Fish Arts ...